Lawmakers are moving to ban AI-only insurance denials, requiring human sign-off for every case. It sounds compassionate, but it locks us into the same slow, opaque, costly system. The smarter move is AI with guardrails — transparency, audits, and contestable rationales — for faster, clearer, more accountable decisions.

FDA approvals of AI-enabled medical devices are accelerating—but not in the way you might expect. While new startups are entering the space, the real winners remain legacy giants like GE and Siemens. An analysis of the latest FDA data reveals a classic case of sustaining innovation, not disruption, as established players integrate AI to reinforce their dominance.